Semin Liver Dis 2019; 39(01): 104-110
DOI: 10.1055/s-0038-1676099
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Primary Sclerosing Cholangitis and Psychological Wellbeing: A Scoping Review

Veronica Ranieri
1   Research and Development Unit, Tavistock Centre, Tavistock and Portman NHS Foundation Trust, London, United Kingdom
2   Department of Science and Technology Studies, University College London, London, United Kingdom
,
Kathy McKay
1   Research and Development Unit, Tavistock Centre, Tavistock and Portman NHS Foundation Trust, London, United Kingdom
3   Institute of Psychology, Health and Society, Waterhouse Building, Block B, Brownlow Street, University of Liverpool, Liverpool, United Kingdom
,
Martine Walmsley
4   PSC Support, Didcot, United Kingdom
,
Robert Senior
1   Research and Development Unit, Tavistock Centre, Tavistock and Portman NHS Foundation Trust, London, United Kingdom
,
Douglas Thorburn
5   Sheila Sherlock Liver Centre and UCL Institute of Liver and Digestive Health, Royal Free Hospital, London, United Kingdom
,
Eilis Kennedy
1   Research and Development Unit, Tavistock Centre, Tavistock and Portman NHS Foundation Trust, London, United Kingdom
6   Research Department of Clinical, Educational & Health Psychology, University College London, London, United Kingdom
› Author Affiliations
Further Information

Publication History

Publication Date:
22 November 2018 (online)

Abstract

Primary sclerosing cholangitis (PSC) is a chronic liver disease resulting from the inflammation and scarring of an individual's hepatic bile ducts. With no curative treatment available and a risk of potentially severe complications and death, it is likely that those diagnosed with the illness may experience impairments in their psychological wellbeing. The aim of this scoping review is to locate, chart, and summarize all available literature on how PSC affects mental health and psychological wellbeing, as well as the factors that may or may not impact on the psychological wellbeing of those who have this diagnosis. This exercise identified five key themes within the literature: prevalence and characteristics of mental health problems, quality of life, unmet needs, medical treatment, and biomarkers. Three key recommendations for clinical practice emerge from this review.

Supplementary Material

 
  • References

  • 1 Lazaridis KN, LaRusso NF. Primary sclerosing cholangitis. N Engl J Med 2016; 375 (12) 1161-1170
  • 2 Chapman R, Fevery J, Kalloo A. , et al; American Association for the Study of Liver Diseases. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51 (02) 660-678
  • 3 Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012; 56 (05) 1181-1188
  • 4 Lazaridis KN, LaRusso NF. The cholangiopathies. Mayo Clin Proc 2015; 90 (06) 791-800
  • 5 Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 2013; 145 (03) 521-536
  • 6 Jussila A, Virta LJ, Pukkala E, Färkkilä MA. Malignancies in patients with inflammatory bowel disease: a nationwide register study in Finland. Scand J Gastroenterol 2013; 48 (12) 1405-1413
  • 7 Lindor KD, Kowdley KV, Harrison ME. ; American College of Gastroenterology. ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol 2015; 110 (05) 646-659 , quiz 660
  • 8 Katon WJ. Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues Clin Neurosci 2011; 13 (01) 7-23
  • 9 PSC Support. Clinical need in PSC and clinically meaningful change: what is important to patients. www.pscsupport.org.uk/unmetneeds . Accessed May 23, 2018
  • 10 Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol 2005; 8: 19-32
  • 11 Björnsson E, Simren M, Olsson R, Chapman RW. Fatigue in patients with primary sclerosing cholangitis. Scand J Gastroenterol 2004; 39 (10) 961-968
  • 12 Benito de Valle M, Rahman M, Lindkvist B, Björnsson E, Chapman R, Kalaitzakis E. Factors that reduce health-related quality of life in patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2012; 10 (07) 769-775.e2
  • 13 Haapamäki J, Tenca A, Sintonen H, Barner-Rasmussen N, Färkkilä MA. Health-related quality of life among patients with primary sclerosing cholangitis. Liver Int 2015; 35 (09) 2194-2201
  • 14 Serigado JM, Barboza KC, Marcus P, Sigal SH. Clinical impact of depression in cirrhosis. Curr Hepatol Rep 2018; 17 (01) 22-32
  • 15 van Os E, van den Broek WW, Mulder PG, ter Borg PC, Bruijn JA, van Buuren HR. Depression in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 2007; 46 (06) 1099-1103
  • 16 Zakharia K, Tabibian A, Lindor KD, Tabibian JH. Complications, symptoms, quality of life and pregnancy in cholestatic liver disease. Liver Int 2018; 38 (03) 399-411
  • 17 Le Strat Y, Le Foll B, Dubertret C. Major depression and suicide attempts in patients with liver disease in the United States. Liver Int 2015; 35 (07) 1910-1916
  • 18 Gotthardt DN, Rupp C, Bruhin M. , et al. Pruritus is associated with severely impaired quality of life in patients with primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 2014; 26 (12) 1374-1379
  • 19 Davis H, De-Nour AK, Shouval D, Melmed RN. Psychological distress in patients with chronic, nonalcoholic, uncomplicated liver disease. J Psychosom Res 1998; 44 (05) 547-554
  • 20 van Ginneken BT, van den Berg-Emons RJ, van der Windt A. , et al. Persistent fatigue in liver transplant recipients: a two-year follow-up study. Clin Transplant 2010; 24 (01) E10-E16
  • 21 Cheung AC, Patel H, Meza-Cardona J, Cino M, Sockalingam S, Hirschfield GM. Factors that Influence health-related quality of life in patients with primary sclerosing cholangitis. Dig Dis Sci 2016; 61 (06) 1692-1699
  • 22 Watanabe A, Inoue T. Transformational experiences in adult-to-adult living-donor liver transplant recipients. J Adv Nurs 2010; 66 (01) 69-81
  • 23 Arndtz K, Hirschfield GM. Quality of life and primary sclerosing cholangitis: the business of defining what counts. Hepatology 2018; 68 (01) 16-18
  • 24 Aberg F, Höckerstedt K, Roine RP, Sintonen H, Isoniemi H. Influence of liver-disease etiology on long-term quality of life and employment after liver transplantation. Clin Transplant 2012; 26 (05) 729-735
  • 25 Pavlides M, Cleland J, Rahman M. , et al. Outcomes after ileal pouch anal anastomosis in patients with primary sclerosing cholangitis. J Crohn's Colitis 2014; 8 (07) 662-670
  • 26 Bryan S, Ratcliffe J, Neuberger JM, Burroughs AK, Gunson BK, Buxton MJ. Health-related quality of life following liver transplantation. Qual Life Res 1998; 7 (02) 115-120
  • 27 Raszeja-Wyszomirska J, Wunsch E, Krawczyk M, Rigopoulou EI, Bogdanos D, Milkiewicz P. Prospective evaluation of PBC-specific health-related quality of life questionnaires in patients with primary sclerosing cholangitis. Liver Int 2015; 35 (06) 1764-1771
  • 28 Younossi ZM, Kiwi ML, Boparai N, Price LL, Guyatt G. Cholestatic liver diseases and health-related quality of life. Am J Gastroenterol 2000; 95 (02) 497-502
  • 29 Ananthakrishnan AN, Beaulieu DB, Ulitsky A. , et al. Does primary sclerosing cholangitis impact quality of life in patients with inflammatory bowel disease?. Inflamm Bowel Dis 2010; 16 (03) 494-500
  • 30 Raszeja-Wyszomirska J, Kucharski R, Zygmunt M, Safranow K, Miazgowski T. The impact of fragility fractures on health-related quality of life in patients with primary sclerosing cholangitis. Hepat Mon 2015; 15 (04) e25539
  • 31 Sarkar M, Watt KD, Terrault N, Berenguer M. Outcomes in liver transplantation: does sex matter?. J Hepatol 2015; 62 (04) 946-955
  • 32 Day E, Best D, Sweeting R. , et al. Predictors of psychological morbidity in liver transplant assessment candidates: is alcohol abuse or dependence a factor?. Transpl Int 2009; 22 (06) 606-614
  • 33 Kalaitzakis E, Simrén M, Olsson R. , et al. Gastrointestinal symptoms in patients with liver cirrhosis: associations with nutritional status and health-related quality of life. Scand J Gastroenterol 2006; 41 (12) 1464-1472
  • 34 Gralnek IM, Hays RD, Kilbourne A. , et al. Development and evaluation of the liver disease quality of life instrument in persons with advanced, chronic liver disease: the LDQOL 1.0. Am J Gastroenterol 2000; 95 (12) 3552-3565
  • 35 Gutteling JJ, de Man RA, van der Plas SM, Schalm SW, Busschbach JJ, Darlington AS. Determinants of quality of life in chronic liver patients. Aliment Pharmacol Ther 2006; 23 (11) 1629-1635
  • 36 Younossi ZM, Boparai N, Price LL, Kiwi ML, McCormick M, Guyatt G. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol 2001; 96 (07) 2199-2205
  • 37 Kalaitzakis E, Benito de Valle M, Rahman M. , et al. Mapping chronic liver disease questionnaire scores onto SF-6D utility values in patients with primary sclerosing cholangitis. Qual Life Res 2016; 25 (04) 947-957
  • 38 Eraydın A, Akarsu M, Derviş Hakim G, Keskinoğlu P, Ellidokuz H. The validity and reliability of “The liver disease symptom index 2.0” for Turkish society. Turk J Gastroenterol 2014; 25 (05) 531-538
  • 39 Jin XY, Khan TM. Quality of life among patients suffering from cholestatic liver disease-induced pruritus: a systematic review. J Formos Med Assoc 2016; 115 (09) 689-702
  • 40 Ypinazar V. Supporting patients with a rare disease. Aust Fam Physician 2015; 44 (09) 644-645
  • 41 Gross CR, Malinchoc M, Kim WR. , et al. Quality of life before and after liver transplantation for cholestatic liver disease. Hepatology 1999; 29 (02) 356-364
  • 42 Martins EB, Chapman RW. Sclerosing cholangitis. Curr Opin Gastroenterol 2000; 16 (05) 444-449
  • 43 Kanwal F, Spiegel BM, Hays RD. , et al. Prospective validation of the short form liver disease quality of life instrument. Aliment Pharmacol Ther 2008; 28 (09) 1088-1101
  • 44 Yang LS, Shan LL, Saxena A, Morris DL. Liver transplantation: a systematic review of long-term quality of life. Liver Int 2014; 34 (09) 1298-1313
  • 45 Belle SH, Porayko MK, Hoofnagle JH, Lake JR, Zetterman RK. ; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Liver Transplantation Database (LTD). Changes in quality of life after liver transplantation among adults. Liver Transpl Surg 1997; 3 (02) 93-104
  • 46 Garcia RF, Garcia CE, McMaster P. Chronic rejection of the liver: the role of immunosuppression. BioDrugs 2000; 14 (05) 283-297
  • 47 Kanwal F, Gralnek IM, Hays RD. , et al. Health-related quality of life predicts mortality in patients with advanced chronic liver disease. Clin Gastroenterol Hepatol 2009; 7 (07) 793-799
  • 48 Rogal SS, Winger D, Bielefeldt K, Szigethy E. Pain and opioid use in chronic liver disease. Dig Dis Sci 2013; 58 (10) 2976-2985
  • 49 Ruppert K, Kuo S, DiMartini A, Balan V. In a 12-year study, sustainability of quality of life benefits after liver transplantation varies with pretransplantation diagnosis. Gastroenterology 2010; 139 (05) 1619-1629 , 1629.e1–1629.e4
  • 50 Noma S, Hayashi A, Uehara M. , et al. Psychosocial predictors of psychiatric disorders after living donor liver transplantation. Int J Psychiatry Clin Pract 2008; 12 (02) 120-126
  • 51 Parvizi Z, Sadati AK, Azarpira N, Tabrizi R, Heydari ST, Lankarani KB. Study of quality of life among liver transplant candidates in Shiraz, Southwestern Iran. Galen Med J 2016; 5 (04) 180-187
  • 52 Davydow DS, Lease ED, Reyes JD. Posttraumatic stress disorder in organ transplant recipients: a systematic review. Gen Hosp Psychiatry 2015; 37 (05) 387-398
  • 53 Wunsch E, Trottier J, Milkiewicz M. , et al. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology 2014; 60 (03) 931-940
  • 54 Olsson R, Boberg KM, de Muckadell OS. , et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005; 129 (05) 1464-1472
  • 55 ter Borg PC, van Os E, van den Broek WW, Hansen BE, van Buuren HR. Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634]. BMC Gastroenterol 2004; 4: 13
  • 56 Tabibian JH, Gossard A, El-Youssef M. , et al. Prospective clinical trial of rifaximin therapy for patients with primary sclerosing cholangitis. Am J Ther 2017; 24 (01) e56-e63
  • 57 Kuiper EM, van Erpecum KJ, Beuers U. , et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology 2010; 52 (04) 1334-1340
  • 58 Gorgun E, Remzi FH, Manilich E, Preen M, Shen B, Fazio VW. Surgical outcome in patients with primary sclerosing cholangitis undergoing ileal pouch-anal anastomosis: a case-control study. Surgery 2005; 138 (04) 631-637 , discussion 637–639
  • 59 Rahman M, Desmond P, Mortensen N, Chapman RW. The clinical impact of primary sclerosing cholangitis in patients with an ileal pouch-anal anastomosis for ulcerative colitis. Int J Colorectal Dis 2011; 26 (05) 553-559
  • 60 Kempinska-Podhorodecka A, Milkiewicz M, Jabłonski D, Milkiewicz P, Wunsch E. ApaI polymorphism of vitamin D receptor affects health-related quality of life in patients with primary sclerosing cholangitis. PLoS One 2017; 12 (04) e0176264
  • 61 Wunsch E, Krawczyk M, Milkiewicz M. , et al. Serum autotaxin is a marker of the severity of liver injury and overall survival in patients with cholestatic liver diseases. Sci Rep 2016; 6: 30847
  • 62 ter Borg PC, Fekkes D, Vrolijk JM, van Buuren HR. The relation between plasma tyrosine concentration and fatigue in primary biliary cirrhosis and primary sclerosing cholangitis. BMC Gastroenterol 2005; 5: 11